Get the Stockscreener App
336.45
0.05%
0.16
Pre-market:
334.98
-1.47
-0.44%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $336.45, with a volume of 2.18M.
It is up +0.05% in the last 24 hours and down -3.82% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$336.29
Open:
$332.32
24h Volume:
2.18M
Relative Volume:
0.83
Market Cap:
$181.68B
Revenue:
$37.30B
Net Income/Loss:
$7.80B
P/E Ratio:
23.40
EPS:
14.3793
Net Cash Flow:
$8.60B
1W Performance:
+1.61%
1M Performance:
-3.82%
6M Performance:
+0.13%
1Y Performance:
+24.40%
1-Day Range:
$330.06
$338.00
1-Week Range:
$327.22
$338.49
52-Week Range:
$261.43
$391.29
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, AZN, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
336.45 | 181.60B | 37.30B | 7.80B | 8.60B | 14.38 |
LLY
Lilly Eli Co
|
1,015.75 | 882.71B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
230.42 | 539.84B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
208.50 | 367.25B | 62.82B | 3.60B | 19.98B | 2.0274 |
AZN
Astrazeneca Plc
|
187.72 | 286.19B | 60.48B | 10.40B | 8.05B | 3.3297 |
NVS
Novartis Ag Adr
|
149.75 | 282.70B | 54.66B | 13.58B | 16.05B | 7.0171 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Hold |
| Mar-10-26 | Initiated | Jefferies | Hold |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Jan-20-26 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-05-25 | Upgrade | Erste Group | Hold → Buy |
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Atria Investments Inc Buys 10,877 Shares of Amgen Inc. $AMGN - MarketBeat
A Look At Amgen (AMGN) Valuation After Q1 Beat Guidance Upgrade And US$300 Million US Expansion - simplywall.st
AMGN: Key products and pipeline assets drive growth, with major investments and strong Q1 results - TradingView
Global Colorectal Cancer Diagnostics and Therapeutics Market Anticipates Impressive Growth Trajectory at a CAGR of ~9% by 2034 | DelveInsight - GlobeNewswire Inc.
Amgen stock (US0311621009): Q1 earnings beat with revenue up 5.8% - AD HOC NEWS
Daiwa Securities Adjusts Price Target on Amgen to $390 From $410, Maintains Outperform Rating - marketscreener.com
Amgen stock (US0311621009): Q1 2026 earnings show net income turnaround - AD HOC NEWS
Amgen Inc. stock outperforms competitors on strong trading day - MarketWatch
Amgen stock (US0311621009): Q1 2026 earnings beat estimates with revenue up 5.8% - AD HOC NEWS
Amgen stock (US0311621009): Biotech leader navigates patent cliffs and pipeline momentum - AD HOC NEWS
Scientific Approach to Obesity - Amgen
Amgen (NASDAQ:AMGN) Stock Unloaded Rep. Maria Elvira Salazar - MarketBeat
Maria Elvira Salazar trades in Amgen, Carrier Global, and Microsoft stocks - Investing.com Australia
Amgen (AMGN) VP Matthew Busch reports 41-share tax-withholding transaction - Stock Titan
Amgen (NASDAQ: AMGN) EVP uses 556 shares to cover tax obligations - Stock Titan
Amgen (NASDAQ: AMGN) HR SVP reports 151-share tax-withholding disposition - Stock Titan
Amgen (NASDAQ: AMGN) SVP reports 93-share tax-withholding disposition on Form 4 - Stock Titan
Amgen (NASDAQ: AMGN) EVP uses 499 shares for equity award tax withholding - Stock Titan
Amgen (NASDAQ: AMGN) EVP disposes 615 shares for tax withholding - Stock Titan
Amgen (NASDAQ: AMGN) CEO has 2,079 shares withheld for taxes - Stock Titan
Amgen (AMGN) EVP Bradner reports 446-share tax-withholding transaction, holds 30,016 shares - Stock Titan
Amgen Late To Raise Double-Taxation Claim, Tax Court Told - Law360
Amgen Inc. stock (US0311621009): Q1 earnings beat with $5.15 EPS - AD HOC NEWS
Amgen Inc. stock underperforms Friday when compared to competitors - MSN
AMGN Fairly Valued by DCF at $292 - GuruFocus
Amgen stock (US0311621009): Pharma giant navigates C-suite transition and Q1 growth - AD HOC NEWS
Swiss Life Asset Management Ltd Reduces Stake in Amgen Inc. $AMGN - MarketBeat
Amgen stock (US0311621009): $300M Puerto Rico investment signals manufacturing expansion - AD HOC NEWS
Nicholas Company Inc. Makes New Investment in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Sold by Securian Asset Management Inc. - MarketBeat
Amgen Inc. (AMGN) Stock Analysis: Evaluating Growth Potential Amid Strong Analyst Ratings - DirectorsTalk Interviews
Amgen’s New Puerto Rico Biologics Investment Might Change The Case For Investing In Amgen (AMGN) - simplywall.st
AMGN Technical Analysis | Trend, Signals & Chart Patterns | AMGEN INC (NASDAQ:AMGN) - ChartMill
Merck, Amgen double down on bad cholesterol to vanquish number 1 killer - BioSpace
Will FDA-Backed Real-Time Trials in SCLC Reframe Amgen's (AMGN) R&D Narrative? - Yahoo Finance
Amgen’s Real Time FDA Trial Pilot Puts Oncology Execution In Focus - Yahoo Finance
NewEdge Wealth LLC Acquires 7,521 Shares of Amgen Inc. $AMGN - MarketBeat
Why (AMGN) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Amgen's Q1 earnings top estimates, 16 drugs deliver double-digit gains - MSN
Standing Bone Strong: Introducing a New Awareness Symbol for Osteoporosis - Amgen
Inside Amgen’s Next-Generation Labs: Powering Faster, Smarter Small Molecule Drug Discovery - Amgen
Amgen Q1 2026 slides: six growth drivers fuel 24% expansion By Investing.com - Investing.com Nigeria
Earnings call transcript: Amgen Q1 2026 beats EPS forecast, stock dips - Investing.com Nigeria
Amgen Q1 2026 slides: six growth drivers fuel 24% expansion - Investing.com
Amgen Inc. stock (US0311621009): U.S. manufacturing push and Q1 2026 results in focus - AD HOC NEWS
Amgen Inc. $AMGN Shares Acquired by Wesbanco Bank Inc. - MarketBeat
Amgen Inc. stock (US0311621009): Biotech giant eyes growth amid patent cliffs and pipeline bets - AD HOC NEWS
Crossmark Global Holdings Inc. Has $15.62 Million Stock Position in Amgen Inc. $AMGN - MarketBeat
Ethic Inc. Boosts Stock Position in Amgen Inc. $AMGN - MarketBeat
Is It Time To Reassess Amgen (AMGN) After A Steady Share Price And Strong DCF Case - simplywall.st
Is Amgen Stock Poised for a Rally? - Trefis
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.40%
0.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):